Author:
Lin Shin-Mao,Yang Szu-Chun,Wu Tzu-I.,Wang Jung-Der,Liu Li-Fan
Abstract
AbstractTo quantify the societal impact of disability in patients with non-small cell lung cancer (NSCLC), this study estimated the disability-free life expectancy (DFLE), loss-of-DFLE and explored their associations with quality-adjusted life expectancy (QALE) and loss-of-QALE. We interlinked national databases and applied a rolling-over algorithm to estimate the lifetime survival function for patients with NSCLC. Using the EuroQOL-5 Dimension (EQ-5D) and Barthel index (BI), we repeatedly measured the quality-of-life and disability functions of NSCLC patients who visited our hospital from 2011 to 2020. Age-, sex-matched referents were simulated from lifetables of the same calendar year of diagnosis. We categorized BI scores ≤ 70 as in need of long-term care and constructed linear mixed models to estimate the utility values and disability scores. We collected 960 cases and 3088 measurements. The proportions of measurements without disability at age 50–64 and in stage I–IIIa, 50–64 and stage IIIb–IV, 65–89 and stage I–IIIa and 65–89 and stage IIIb–IV were 97.3%, 89.3%, 94.8%,78.3%, corresponding to DFLEs of 15.3, 2.4, 6.8, 1.2 years and losses-of-DFLE of 8.1, 20.7, 4.0, 8.6 years, respectively, indicating that advanced stage had a stronger effect than old age. Survivors in advanced stages showed increased demands for assistance in almost all subitems. The DFLEs seemed to be approximate to the QALEs and the latter were shorter than the former due to discomfort and depression. From a societal perspective, future health technology assessment should consider the impact of lifetime duration of functional disability. Early diagnosis of NSCLC may decrease the burden of long-term care.
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. World Health Organization: International Agency for Research on Cancer. Estimated Number of Deaths in 2020, All Cancers, Both Sexes, All Ages. https://gco.iarc.fr/today/online-analysis-pie?v=2020&mode=population&mode_population=continents&population=900&populations=900&key=total&sex=0&cancer=39&type=1&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=7&group_cancer=1&include_nmsc=1&include_nmsc_other=1&half_pie=0&donut=0 (2020).
2. Ministry of Health and Welfare. Statistics on the Cause of Death in Taiwan. https://www.mohw.gov.tw/cp-5017-61533-1.html (2021).
3. Cancer Incidence Data from the Ministry of Health and Welfare, Taiwan. https://ws.ndc.gov.tw/Download.ashx?u=LzAwMS9hZG1pbmlzdHJhdG9yLzEwL3JlbGZpbGUvNTY3Mi80MzAwLzAwMTIwOTBfMS5wZGY%3D&n=MDMu6ZW35pyf54Wn6K236ZyA5rGC6KmV5LywLeacn%2Bacq%2BWgseWRiiAgICAgMjAwOTA3MTEgdmVyc2lvbi5wZGY%3D&icon=..pdf (2009).
4. Doroshow, D. B. et al. Immunotherapy in non-small cell lung cancer: Facts and hopes. Clin. Cancer Res. 25, 4592–4602. https://doi.org/10.1158/1078-0432.Ccr-18-1538 (2019).
5. Garon, E. B. et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: Results from the phase I KEYNOTE-001 Study. J. Clin. Oncol. 37, 2518–2527. https://doi.org/10.1200/jco.19.00934 (2019).